Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
Amazon and two other American titans are trying to shake up health care by experimenting with their own employees’ coverage. By Chinese standards, they’re behind the curve.
Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
Food allergy has been referred to as the second wave of the allergy epidemic, asthma being the first.
A new IVF method that takes thousands of pictures of embryos to select the best eggs has increased the likelihood of a baby being born by 25 percent.
Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
Scholar Rock has raised $47 million to take its treatment for spinal muscular atrophy (SMA) into the clinic. The series C tees up Scholar Rock to find out whether its myostatin blocker can best the underwhelming performance of one-time rivals from companies including Novartis.
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced that the European Commission (EC) granted Marketing Authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years, and in adult patients.1 The approval – which authorizes Shire to market lyophilized ONCASPAR in the 28 member states of the European Union (EU), as well as Iceland, Liechtenstein and Norway – follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12.
For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.